Altimmune to present Phase 2 alcohol‑use‑disorder trial data at The Liver Meeting
Altimmune announced that its RECLAIM Phase 2 trial of pemvidutide will be presented on November 9, 2026, at the AASLD The Liver Meeting in Denver. The double‑blind, placebo‑controlled study of 2.4 mg weekly pemvidutide in about 100 patients showed a statistically significant reduction in heavy‑drinking days and met key secondary FDA‑recognized endpoints. The company also scheduled an End‑of‑Phase 2 meeting with the FDA in December to discuss a Phase 3 program.
Why it matters
The announcement triggered a 7% drop in Altimmune’s share price, reflecting market reaction to the data release. The upcoming FDA meeting could shape the timeline for a Phase 3 trial and potential regulatory approval.
Key facts
- 1Altimmune will present the RECLAIM Phase 2 data on Monday, November 9, 2026, at The Liver Meeting in Denver. stocktitan.net
- 2The trial evaluated once‑weekly pemvidutide 2.4 mg versus placebo over 24 weeks. investing.com
- 3Approximately 100 patients with BMI > 25 kg/m² were randomized 1:1 to pemvidutide or placebo. stocktitan.net
- 4The primary endpoint was the change from baseline in average heavy‑drinking days per week, which was significantly reduced versus placebo. investing.com
- 5Key secondary endpoints, including WHO Risk Drinking Level reduction and zero heavy‑drinking days, were also met. stocktitan.net
- 6Altimmune plans an End‑of‑Phase 2 meeting with the FDA in December to discuss the Phase 3 registrational program. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.